Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)

NCT04262284 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT04262284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04262284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)
Lead sponsor
CSL Behring
Phase
Observational
Overall status
Completed
Start date
October 18, 2019
Completion date
May 6, 2024
Enrollment
15 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alpha-1 antitrypsin deficiency